Earnings
Atea Says $200 Million In Debt Could Cover Its Drug Launch Without Selling Shares
Atea received $65 million at closing, while access to another $135 million depends on milestones and other conditions.
Atea Pharmaceuticals (AVIR) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Atea received $65 million at closing, while access to another $135 million depends on milestones and other conditions.
SEC Filings
Cash and investments declined to $191.2 million, while Hercules Capital borrowing supports preparations for a possible U.S. launch.
SEC Filings
The financing carries a 9.35% minimum interest rate and pledges substantially all assets, including intellectual property.
SEC Filings
Kevin Tang's firm and its affiliated funds list shared voting power over all 4,814,700 shares, and say they hold them without seeking control.